David Hutton

Articles

Late-breaking: Janssen announces data from 2 gene therapy programs

October 02, 2022

Janssen noted that results from Phase 1/2 MGT009 study demonstrate safety profile of investigational gene therapy botaretigene sparoparvovec (AAV-RPGR) and suggest sustained vision improvement in patients with X-linked retinitis pigmentosa.

LUNA: First patient dosed with Ixo-vec in Phase 2 trial for treatment of wet AMD

September 17, 2022

LUNA trial will evaluate the 2x10^11 vg/eye (2E11) and a new lower 6x10^10 vg/eye (6E10) dose of Ixo-vec, with enhanced prophylactic steroid regimens in patients requiring frequent anti-VEGF injections. Interim data anticipated throughout 2023.

PHOTON, PULSAR trials: Aflibercept meets primary endpoints in safety, efficacy

September 10, 2022

Regeneron announced that the primary endpoints were met in two pivotal trials investigating novel aflibercept 8 mg with 12- and 16-week dosing regimens in patients with diabetic macular edema and wet age-related macular degeneration.

First patient enrolled in Phase 2 study of D-4517.2 for treatment of wet AMD, DME

September 08, 2022

The first stage of the study will evaluate the safety and relative pharmacodynamic effect of different doses of subcutaneously administered D-4517.2 compared to intravitreal injection of aflibercept, an approved therapy, in both wet AMD and DME patients up to 12 weeks.

First US patient with dry AMD dosed with autologous stem cell therapy

September 08, 2022

According to the National Institutes of Health, the therapy was derived from the patient’s blood by converting blood cells to iPS cells which were then programmed to become retinal pigment epithelial cells, which were surgically implanted as a patch of tissue.

OCS-01 improves macular thickness, visual acuity in patients with DME, according to Phase 2 data

September 07, 2022

According to a presentation by Oculis at EURETINA, the dataset shows that OCS-01 eye drops were more effective than vehicle in reducing central macular thickness and improving visual acuity in patients with DME as per the pre-defined criteria for statistical superiority in the study protocol.